61032-41-5

Basic information

• Product Name: Methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate
• Synonyms: Methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate;4-Benzyloxy-5-methoxy-2-nitrobenzoic acid methyl ester;Methyl 5-methoxy-2-nitro-4-(benzyloxy)benzoate;ethyl 4-(benzyloxy)-5-Methoxy-2-nitrobenzoate;Benzoic acid, 5-Methoxy-2-nitro-4-(phenylMethoxy)-, Methyl ester
• CAS NO: 61032-41-5
• Molecular Formula: C₁₆H₁₅NO₆
• Molecular Weight: 317
• Mol File: 61032-41-5.mol
• Article Data: 40

Chemical Properties

• Boiling Point: 482.4±40.0 °C(Predicted)
• Appearance: /
• Density: 1.280
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate(61032-41-5)
• EPA Substance Registry System: Methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate(61032-41-5)

Safety Data

• Hazardous Substances Data: 61032-41-5(Hazardous Substances Data)

Usage

General Description

Methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate is a chemical compound that belongs to the class of benzoates. It is a derivative of benzoic acid and contains a nitro group, a methoxy group, and a benzyloxy group attached to the benzene ring. Methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate is often used in organic synthesis and medicinal chemistry as a building block for the production of various pharmaceuticals and fine chemicals. Its properties and uses make it a valuable intermediate in the synthesis of complex organic molecules.

Upstream product

• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 100-39-0 benzyl bromide 
• 91203-74-6 4-benzyloxy-3-methoxybenzoic acid benzyl ester 
• 67-56-1 methanol 
• 60547-92-4 4-(benzyloxy)-5-methoxy-2-nitrobenzoic acid 
• 56441-97-5 methyl 4-(benzyloxy)-3-methoxybenzoate 
• 108-24-7 acetic anhydride 
• 111627-40-8 methyl 4-(3-chloropropoxy)-3-methoxybenzoate 
• 2426-87-1 3-methoxy-4-(phenylmethoxy)benzaldehyde 
• 121-33-5 vanillin 
• 121-34-6 3-methoxy-4-hydroxybenzoic acid 
• 100-44-7 benzyl chloride 
• 27883-60-9 4-hydroxy-5-methoxy-2-nitrobenzoic acid methyl ester 
• 1486-53-9 4-(benzyloxy)-3-methoxybenzoic acid 

Downstream Products

• 253777-48-9 2-(allyl-trifluoroacetyl)-amino-4-benzyloxy-N-3-(bromopropyl)-5-methoxy-benzamide 
• 253777-50-3 8-benzyloxy-4-(3-bromopropyl)-7-methoxy-1-trifluoroacetyl-1,4-dihydrobenzo[e][1,4]diazepin-5-one 
• 253777-44-5 N-allyl-7-benzyloxy-6-methoxyisatoic anhydride 
• 155666-33-4 2-amino-4-benzyloxy-5-methoxybenzoic acid 
• 849795-72-8 (11aS)-8-benzyloxy-7-methoxy-1,2,3,9,10,11,11a-hexahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one 
• 253777-45-6 7-benzyloxy-6-methoxyisatoic anhydride 
• 1188908-02-2 1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-hydroxy-6-methoxyquinazolin-4-yloxy)phenyl)urea 
• 1188908-03-3 C₂₂H₁₉N₃O₃ 
• 1188908-04-4 4-(3-aminophenoxy)-6-methoxyquinazolin-7-ol 
• 179688-01-8 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one 
• 162012-72-8 7-hydroxy-6-methoxy-3,4-dihydroquinazolin-4-one 
• 179688-02-9 7-acetoxy-6-methoxy-3,4-dihydroquinazolin-4-one 
• 179688-03-0 4-chloro-6-methoxyquinazolin-7-yl acetate 
• 1622396-50-2 C₃₂H₃₈N₆O₅ 

Relevant articles and documents

VISUAL DETECTION OF PBD INDUCED DNA CROSSLINKS

The present invention relates to the field of oncology, laboratory tools and methods, and especially anti-tumor DNA crosslinking agents. Most patients with advanced solid tumors develop resistance to chemotherapy due to the ability of cancer cells to repair or tolerate sustained DNA damages. The inventors showed that the compounds according to the present invention allow the detection and visualization of alkylated DNA damages induced by PBDs without altering their DNA crosslinking ability. This enables the study of the effect and properties of PBDs. In particular, the present invention relates new derivates of PBD molecules and their synthesis. The present invention also relates to a method for visualizing DNA crosslinking; to a method for assessing the resistance of a tumor to a crosslinking agent and to a method for identifying a molecule or treatment for improving the efficiency of a crosslinking agent.

Structure–activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy

As a privileged scaffold, the quinazoline ring is widely used in the development of EGFR inhibitors, while few quinazoline-based MET inhibitors are reported. In our ongoing efforts to develop new MET-targeted anticancer drug candidates, a series of quinaz

NOVEL BENZODIAZEPINE DERIVATIVES AND USES THEREOF

The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.